SCHEMBL719952

SCHEMBL719952

Cc1ncn(-c2ccc(N)cc2)n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 6/20 0.42
MKNK1 Q9BUB5 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
MAPT P10636 6/20 0.37
LMNA P02545 2/20 0.37
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
SMN1; SMN2 Q16637 3/20 0.37
TSHR P16473 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
KMT2A Q03164 4/20 0.36
KDM4E B2RXH2 3/20 0.36
ALDH1A1 P00352 3/20 0.36
MEN1 O00255 3/20 0.36
GAA P10253 2/20 0.36
TP53 P04637 2/20 0.36
HPGD P15428 1/20 0.36
CASP1 P29466 1/20 0.36
CASP7 P55210 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL5799102 0.98 MAPK10 (0.41) MAPK10MKNK1MKNK2MAPTLMNA
SCHEMBL13183810 0.83 ALDH1A1 (0.45) MAPK10MAPTLMNASMN1; SMN2KMT2A
SCHEMBL13183655 0.81 NOTUM (0.51) MAPK10MAPTLMNANPC1RAB9A
SCHEMBL4873943 0.80 MAPK10 (0.42) MAPK10MAPTLMNAKMT2AALDH1A1
SCHEMBL15299233 0.80 MAPK10 (0.42) MAPK10MAPTLMNANPC1RAB9A
SCHEMBL16202024 0.80 MAPK10 (0.42) MAPK10LMNANPC1RAB9ASMN1; SMN2
SCHEMBL719104 0.80 MAPT (0.46) MAPK10MKNK1MKNK2MAPTLMNA
SCHEMBL16202009 0.80 NOTUM (0.46) MAPK10NPC1RAB9AL3MBTL1KMT2A
SCHEMBL3703711 0.79 NOS3 (0.44) MAPK10MAPTLMNASMN1; SMN2KDM4E
SCHEMBL4088306 0.79 MAPK10 (0.48) MAPK10MAPTSMN1; SMN2KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1951713-A1 PROCESS FOR THE LARGE SCALE PRODUCTION OF RIZATRIPTAN BENZOATE Matrix Laboratories Ltd (IN) 2008-08-06 EP claimed
WO-2007054979-A1 PROCESS FOR THE LARGE SCALE PRODUCTION OF RIZATRIPTAN BENZOATE MATRIX LABORATORIES LTD (IN) 2007-05-18 WO claimed
CN-115724780-B Acylthiourea compound based on hydrophobic tag, preparation method thereof and application of acylthiourea compound in resisting influenza A virus 武汉大学 2024-04-26 CN disclosed
CN-115724780-A Acyl thiourea compound based on hydrophobic label, preparation method thereof and application of acyl thiourea compound in resisting influenza A virus 武汉大学 2023-03-03 CN disclosed
CN-115073385-A Application of microchannel continuous flow reaction technology in synthesis of rizatriptan benzoate 湖北欧立制药有限公司 2022-09-20 CN disclosed
CN-110478344-B Application of acylthiourea compound in preparation of anti-influenza B virus medicine 武汉大学 2022-07-19 CN disclosed
CN-109476670-B Bicyclic heteroaryl derivatives 豪夫迈·罗氏有限公司 2022-06-28 CN disclosed
EP-3564232-B1 BMP-SIGNAL-INHIBITING COMPOUND RIKEN (JP) 2022-01-26 EP disclosed
EP-3342765-B1 CATHEPSIN K INHIBITOR AND APPLICATION THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2021-09-15 EP disclosed
EP-3481829-B1 FUSED PYRIMIDINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2021-04-07 EP disclosed
US-10954216-B2 BMP-signal-inhibiting compound RIKEN (JP) 2021-03-23 US disclosed
WO-2010132015-A1 NEW COMPOUNDS MODULATING GAMMA-SECRETASE AND THEIR USE IN THE TREATMENT OF ALPHA BETA RELATED PATHOLOGIES, SUCH AS ALZHEIMER'S DISEASE ASTRAZENECA AB (SE) 2010-11-18 WO disclosed
WO-2010083141-A1 BICYCLIC COMPOUNDS FOR THE REDUCTION OF BETA-AMYLOID PRODUCTION BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-22 WO disclosed
EP-2200436-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS The Scripps Research Institute (US) 2010-06-30 EP disclosed
CN-101735162-A Preparation method of rizatriptan benzoate midbody TIANJIN WEIJIE KAIHUA TECHNOLO 2010-06-16 CN disclosed
WO-2009032861-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2009-03-12 WO disclosed
WO-2009032861-A1 SUBSTITUTED PYRIMIDINYL-AMINES AS PROTEIN KINASE INHIBITORS THE SCRIPPS RESEARCH INSTITUTE (US) 2009-03-12 WO disclosed
US-20090062550-A1 Process for the Large Scale Production of Rizatriptan Benzoate MATRIX LABORATORIES LTD (IN) 2009-03-05 US disclosed
EP-1951713-A1 PROCESS FOR THE LARGE SCALE PRODUCTION OF RIZATRIPTAN BENZOATE Matrix Laboratories Ltd (IN) 2008-08-06 EP disclosed
WO-2007054979-A1 PROCESS FOR THE LARGE SCALE PRODUCTION OF RIZATRIPTAN BENZOATE MATRIX LABORATORIES LTD (IN) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10954216-B2 BMP-signal-inhibiting compound BMP1, BMP2, BMP4 MAPK10 153/4885MKNK1 217/4885MKNK2 174/4885
US-20090062550-A1 Process for the Large Scale Production of Rizatriptan Benzoate DPP4, HTR3A, SI MAPK10 4750/4885MKNK1 3833/4885MKNK2 3907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.